Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration [PDF]
New England Journal of Medicine, 2006 Peter K Kaiser, Jeffrey S Heier
exaly +3 more sources
Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration [PDF]
Cost Effectiveness and Resource Allocation, 2008 Background Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients with neovascular age-related macular degeneration, but it is expensive, and efficacy beyond 2 years is uncertain.
Matthews Jane P +2 more
doaj +2 more sources
Treatment of age-related macular degeneration: focus on ranibizumab
Clinical Ophthalmology, 2008 Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter SzurmanTuebingen University Eye Center, University of Tuebingen, GermanyAbstract: Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms of VEGF-A ...
Martin S Spitzer +4 more
doaj +3 more sources
Comparison of three loading doses of bevacizumab and ranibizumab for macular edema due to branch retinal vein occlusion [PDF]
BMC OphthalmologyObjective To compare the effectiveness and safety of three loading doses of bevacizumab and ranibizumab for macular edema (ME) due to branch retinal vein occlusion (BRVO). Methods This retrospective study included 49 patients with BRVO. The patients were
Sibel Coşkun Akdemir +1 more
doaj +2 more sources
Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration [PDF]
, 2009 PURPOSE: To investigate the efficacy of vascular endothelial growth factor-specific (VEGF) monoclonal antibodies in the treatment of choroidal neovascularization secondary to age-related macular degeneration (AMD) that does not extend beneath the foveal ...
Aaron Brock Roller, Miguel Hage Amaro
openalex +5 more sources
Assessment of mouse VEGF neutralization by ranibizumab and aflibercept.
PLoS ONE, 2022 PurposeTo assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial growth factor (VEGF), both in vivo and in vitro.MethodsIn vivo, the effect of intravitreal injection of ranibizumab and aflibercept on oxygen induced ...
Yusuke Ichiyama +7 more
doaj +1 more source
Inhibitory effect of tenomodulin versus ranibizumab on in vitro angiogenesis [PDF]
International Journal of Ophthalmology, 2017 AIM: To evaluate anti-angiogenic effect of tenomodulin (TNMD) and ranibizumab on cell proliferation and capillary-like morphogenesis of vascular endothelial cells under the stimulation of vascular endothelial growth factor (VEGF) in vitro.
Wei Wang +4 more
doaj +1 more source
6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome [PDF]
International Journal of Ophthalmology, 2016 AIM: To compare visual acuity and central macular thickness (CMT) changes in neovascular age related macular degeneration patients treated with either 6 weekly bevacizumab regimen or 4 weekly ranibizumab on an as required basis.
Patrick J Chiam +3 more
doaj +1 more source
Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports [PDF]
, 2020 Introduction: Since vascular endothelial growth factor (VEGF) regulates several aspects of the central nervous system, particularly in dopaminergic neurons, VEGF inhibitors may be linked to Parkinson-like events and dementia, or variants of these ...
Avery +30 more
core +3 more sources
One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study [PDF]
International Journal of Ophthalmology, 2018 AIM: To assess the effectiveness and safety of ranibizumab 0.5 mg in Taiwanese patients with polypoidal choroidal vasculopathy (PCV) by performing a retrospective exploratory subgroup analysis of the REAL study.
San-Ni Chen +8 more
doaj +1 more source